KOSDAQ - Delayed Quote KRW

ABL Bio Inc. (298380.KQ)

68,700.00

+3,800.00

+(5.86%)

At close: 3:30:22 PM GMT+9

ABL Bio and GSK link on neurodegenerative conditions

GSK will pay ABL up to $99.39m in upfront and near-term payments.

Pharmaceutical Technology 15 days ago

298380.KQ
+5.86%
ABL Bio Announces Grabody-B Brain Delivery Platform License Agreement with GSK to Develop Novel Medicines for Neurodegenerative Diseases

ABL Bio Inc. (KOSDAQ: 298380), a clinical-stage biotech company developing bispecific antibody technology for immuno-oncology and neurodegenerative diseases, announced a worldwide licensing agreement enabling GSK to develop novel medicines for neurodegenerative diseases by utilizing ABL Bio's blood-brain barrier (BBB) shuttle platform, Grabody-B. The agreement aims to develop multiple programs for novel targets across therapeutic modalities including antibody, polynucleotide or oligonucleotides,

PR Newswire 15 days ago

298380.KQ
+5.86%
298380.KS
ABL Bio Announces Clinical Collaboration to Evaluate ABL103 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Solid Tumors

ABL Bio (CEO Sang Hoon Lee), a company specializing in bispecific antibodies, today announced that it has entered into a clinical trial collaboration and supply agreement with MSD (a subsidiary of Merck & Co., Inc., Rahway, NJ, USA), to evaluate ABL103 in combination with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in patients with advanced or metastatic solid tumors.

PR Newswire 6 months ago

298380.KQ
+5.86%
298380.KS

Performance Overview

Return	298380.KQ	KOSPI Composite Index (^KS11)
YTD	+129.77%	+3.63%
1-Year	+198.05%	-5.43%
3-Year	+184.47%	-8.06%